Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

@article{Grbic2008IncidenceOO,
  title={Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.},
  author={John T Grbic and Regina Landesberg and Shou-qing Lin and Peter Mesenbrink and Ian R. Reid and Ping Chung Leung and Noem{\'i} Casas and Chris Recknor and Ye Hua and Pierre Dominique Delmas and Erik Fink Eriksen},
  journal={Journal of the American Dental Association},
  year={2008},
  volume={139 1},
  pages={
          32-40
        }
}
BACKGROUND The authors determined incidence of osteonecrosis of the jaw (ONJ) in a large, prospective three-year clinical trial of zoledronic acid in women with postmenopausal osteoporosis (PMO). METHODS A total of 7,714 women with PMO received intravenous zoledronic acid 5 mg or a placebo. No spontaneous reports of ONJ were received. An independent, blinded adjudication committee searched the trial's adverse event database by using 60 terms. On an ongoing basis, the committee reviewed the… 

Tables from this paper

The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.

In the clinically diverse group of 5,903 patients who received ZOL in five clinical trials, ONJ incidence was less than one in 14,200 patient treatment-years, and data from four clinical trials indicated that S-CTx levels lower than 0.15 ng/mL were common among patients receiving ZOL for treatment of OP and were not associated with ONJ.

Medication-Related Osteonecrosis of the Jaws From Once Per Year Intravenous Zoledronic Acid (Reclast): Report of 4 Cases

4 cases of patients who had a history of long-term oral antiresorptive therapy and now were taking the once-yearly IV zoledronic acid (Reclast) and soon developed MRONJ after completing surgery of the maxilla and mandible are reported.

Closing in on the Puzzle of ONJ.

  • M. Glick
  • Medicine
    Journal of the American Dental Association
  • 2008
These two articles contribute to a growing body of knowledge that, in time, may clarify the epidemiology of an oral lesion that has puzzled scientists for the past five years and help clarify the potential adverse effects of dental treatment in patients taking bisphosphonates.

Epidemiology and pathogenesis of osteonecrosis of the jaw

The pathogenesis of ONJ is uncertain: the toxic effects of bisphosphonates in a wide variety of cells could increase susceptibility to infections in the oral cavity or impair mucosal healing, and denosumab might interfere with monocyte and macrophage function.

Osteonecrosis related to once-yearly zoledronic acid treatment in an osteoporotic patient after dental implant.

Dentists and oral surgeons should be alert to the possibility of osteonecrosis related to the use of once-yearly injections of zoledronic acid for the treatment of postmenopausal osteoporosis.

Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report.

This paper reports the case history of a patient who had bisphosphonate-associated osteonecrosis of the jaw (ONJ) in which adjunctive treatment with teriparatide was used, which is the third case history reported in the literature in which teriparetide was successfully used as adjunct therapy in ONJ.

Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis

  • R. Rizzoli
  • Medicine
    Therapeutic advances in musculoskeletal disease
  • 2010
Zoledronic acid 5 mg once-yearly infusion has demonstrated marked efficacy in the treatment and Prevention of primary and secondary osteoporosis, with a combination of fracture risk reduction and prevention of bone loss at key sites.
...

References

SHOWING 1-10 OF 49 REFERENCES

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

The data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis.

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease.

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Conservative débridement of necrotic bone, pain control, infection management, use of antimicrobial oral rinses, and withdrawal of bisphosphonates are preferable to aggressive surgical measures for treating this condition.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor for this complication and length of exposure seems to be the most important risk factor.

Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

Osteonecrosis of the jaws is strongly associated with the use of aminobisphosphonates, and the mechanism of disease is probably severe suppression of bone turnover, and possible mechanisms of etiopathogenesis are suggested.

Bisphosphonates and oral cavity avascular bone necrosis: A review of 12 cases.

  • N. SalesiR. Pistilli E. Veltri
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
It appears that the pathogenesis of this osteonecrotic process is most consistent with localized vascular insufficiency, and the mechanism by which bisphosphonates could compromise bone vascularity may be related to its effect on the osteoclasts.

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

It is suggested that incremental changes in medication-taking habits could improve clinical outcomes of osteoporosis treatment and that increasing refill compliance levels were associated with progressively lower fracture rates.

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

  • A. BadrosD. Weikel T. Meiller
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
ONJ appears to be time-dependent with higher risk after long-term use of bisphosphonates in older MM patients often after dental extractions, and trials addressing the benefits/risks of continuing bisph phosphonate therapy are needed.

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.